Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease

Respiratory Research

Irma Godoy¹  Camila R Corrêa¹  Corina Corrêa¹  Laura MO Caram¹  Suzana E Tanni¹  Renata Ferrari¹ 

[1] Faculdade de Medicina de Botucatu, Univ Estadual Paulista, Unesp, Disciplina de Pneumologia, Botucatu, São Paulo, Brazil

关键词: Chronic Obstructive Pulmonary Disease;    Exercise;    Biomarkers;    Inflammation;   

Others  :  796524
DOI  :  10.1186/1465-9921-14-24

 received in 2012-10-02, accepted in 2013-02-17,  发布年份 2013

【 摘 要 】

Background

Past studies have shown that mean values of Interleukin-6 (IL-6) and C-reactive protein (CRP) do not change significantly in COPD patients over a one-year period. However, longer period follow-up studies are still lacking. Thus, the aim of this study is to evaluate plasma CRP and IL-6 concentration over three years in COPD patients and to test the association between these inflammatory mediators and disease outcome markers.

Methods

A cohort of 77 outpatients with stable COPD was evaluated at baseline, and 53 (mean FEV₁, 56% predicted) were included in the prospective study. We evaluated Interleukin-6 (IL-6), C-reactive protein (CRP), six-minute walking distance (6MWD), and body mass index (BMI) at baseline and after three years. Plasma concentration of IL-6 was measured by high sensitivity ELISA, and CRP was obtained by high sensitivity particle-enhanced immunonephelometry.

Results

IL-6 increased significantly after 3 years compared to baseline measurements [0.8 (0.5-1.3) vs 2.4 (1.3-4.4) pg/ml; p < 0.001] and was associated with worse 6MWD performance. In the Cox regression, increased IL-6 at baseline was associated with mortality [Hazard Ratio (95% CI) = 2.68 (0.13, 1.84); p = 0.02]. CRP mean values did not change [5 (1.6-7.9) vs 4.7 (1.7-10) pg/L; p = 0.84], although eleven patients (21%) presented with changes >3 mg/L in CRP after 3 years.

Conclusions

The systemic inflammatory process, evaluated by IL-6, seems to be persistent, progressive and associated with mortality and worse physical performance in COPD patients.

Trial registration

No.:NCT00605540

【 授权许可】

   
2013 Ferrari et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Global Initiative for Chronic Obstructive Lung Disease guideline: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2010). Global Initiative for Chronic Obstructive Lung Disease; website. http://www.goldcopd.com/ webcite. Accessed June 15 2012
• [2]Gan WQ, Man SFP, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
• [3]Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I: Smoking and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010, 7:29. BioMed Central Full Text
• [4]Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AM: Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2007, 61:17-22.
• [5]Garrod R, Marshall J, Barley E, Fredericks S, Hagan G: The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease. Prim Care Respir J 2007, 16:236-240.
• [6]Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874.
• [7]Kishimoto T: The biology of interleukin-6. Blood 1989, 1989(74):1-10.
• [8]Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, Vestbo J, Singh D: The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis J 2009, 4:149-156.
• [9]Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ: Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1414-1418.
• [10]Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C- reactive protein in patients with COPD, control smokers, and non-smokers. Thorax 2006, 61:23-28.
• [11]Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B: Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7:e37483.
• [12]Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A: Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072.
• [13]Pinto-Plata V, Casanova C, Mullerova H, de Torres JP, Corado H, Varo N, Cordova E, Zeineldine S, Paz H, Baz R, Divo M, Cortopassi F, Celli BR: Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res 2012, 13:71. BioMed Central Full Text
• [14]Rabe KF: Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011, 163:53-67.
• [15]Jardim JR, Oliveira JA, Nascimento O: II Consenso Brasileiro de DPOC. J Bras Pneumol 2004, 30(Suppl 5):1-42.
• [16]American Thoracic Society statement: Standardization of spirometry – Update. Am Rev Respir Dis 1987, 136:1285-1298.
• [17]American Thoracic Society statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
• [18]Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F: Validação do Modified Pulmonary Functional Status and Dyspnea Questionnaire e da escala do Medical Research Council para o uso em pacientes com doença pulmonar obstrutiva crônica no Brasil. J Bras Pneumol 2008, 34:1008-1018.
• [19]Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
• [20]Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a Combined Comorbidity Index. J Clin Epidemiol 1994, 47:1245-1251.
• [21]R Development Core Team: R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
• [22]Ferrari R, Tanni SE, Faganello MM, Caram LM, Lucheta PA, Godoy I: Three-year follow-up study of respiratory and systemic manifestations of chronic obstructive pulmonary disease. Braz J Med Biol Res 2011, 44:46-52.
• [23]Rincon M: Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012, 33:571-577.
• [24]Mehrotra N, Freire AX, Bauer DC, Harris TB, Newman AB, Kritchevsky SB, Meibohm B: Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol 2010, 20:223-232.
• [25]Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H: Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011, 140:331-342.
• [26]de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR: C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343.
• [27]Man SFP, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
• [28]Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.
• [29]Sin DD, Man SF: Interleukin-6: a red herring or a real catch in COPD? Chest 2008, 133:4-6.
• [30]Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, O'Connor GT, Benjamin EJ: Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008, 133:19-25.
• [31]Kishimoto T: Interleukin-6: from basic science to medicine–40 years in immunology. Annu Rev Immunol 2005, 23:1-21.
• [32]Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Fumiki Yoshihara F, Nakamura S, Kawano Y: Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: Comparison with C-reactive protein. Cytokine 2011, 53:342-346.
• [33]Jenny NS, French B, Arnold AM, Strotmeyer ES, Cushman M, Chaves PH, Ding J, Fried LP, Kritchevsky SB, Rifkin DE, Sarnak MJ, Newman AB: Long-term assessment of inflammation and healthy aging in late life: The Cardiovascular Health Study All Stars. Gerontol A Biol Sci Med Sci 2012, 2012(67):970-976.
• [34]Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ, Marsh AP, Kritchevsky SB, Nicklas BJ: Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci 2009, 64:455-461.
• [35]Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB: Inflammatory markers are associated with ventilator limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61:10-16.